Ascendis Pharma

Youtube Subscribe

Open: 76.44 Close: 76.98 Change: 0.54

How to know if Ascendis Pharma Stock is a risky investment without reading the whole internet.

How much time have you spent trying to decide whether investing in Ascendis Pharma? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ascendis Pharma are: …

Concept Map

Semantic Network

Stock Summary

Ascendis Pharma A/S focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD) The company also develops TransCon Growth Hormone for treating pediatric.

Today's Summary

Pomerantz LLP is investigating claims on behalf of investors of Ascendis Pharma A/S (ASND) Focused on bringing TransCon™ PTH to U.S. Focused. on bringing. TransCon PTH to. U.K. is a defense world.

Today's News

Pomerantz LLP is investigating claims on behalf of investors of Ascendis Pharma A/S (ASND) Focused on bringing TransCon™ PTH to U.S. Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ascendis Pharma A/S - ASND. The consensus price target hints at a 34.6% upside potential. Ascendis Pharma A/S (NASDAQ:ASND) receives average recommendation of “moderate buy” from analysts - defense world. Ascendis pharma a/s (nasdaq:asnd) (NASdaq:AsND) Receives Average recommendation of. “We look forward to sharing this initial dose escalation data, which will guide our selection of the recommended Phase Analysts are optimistic about the future of Ascendis Pharma A/S with a consensus rating of “Moderate Buy,” based on data from Bloomberg.com. Despite missing analysts consensus estimates in February with a negative EPS of $3.78.

Stock Profile

"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark."

Keywords

Are looking for the most relevant information about Ascendis Pharma? Investor spend a lot of time searching for information to make investment decisions in Ascendis Pharma. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ascendis Pharma are: Pharma, AS, Ascendis, consensus, Pomerantz, ASND, recommendation, and the most common words in the summary are: pharmaceutical, therapeutic, pharma, ascendis, patent, application, inc, . One of the sentences in the summary was: Focused. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #pharmaceutical #therapeutic #pharma #ascendis #patent #application #inc.

Read more →

Youtube Subscribe

---